EDIT Stock Analysis: Buy, Sell, or Hold?

EDIT - Editas Medicine, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
$2.47
0.24 (10.76%) ▲
5d: +9.78%
30d: +14.88%
90d: +17.62%
BUY
MODERATE Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation

EDIT is down 7.1% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 1,180 OI. Call ratio: 92% View Scanner →

Strength: 7.7/10

Get Alerted When EDIT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: EDIT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.

In-depth Analysis How we analyze

Valuation Analysis: EDIT is currently trading at $2.47, which is considered slightly high relative to its 30-day fair value range of $2.05 to $2.48.

Technical Outlook: Technically, EDIT is in a strong uptrend. The price is approaching resistance at $2.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.8% recently.

Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+122.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Fair Price Range $2.05 - $2.48
Company Quality Score 51/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 72.1%

All Signals

  • NEUTRAL: Mixed technical signals (55/100)
  • BULLISH: High volume confirmation
  • BULLISH: Strong upward momentum (+10.8%)
  • BULLISH: Trading 122.7% below Wall St target ($5.50)

Fair Price Analysis

30-Day Fair Range $2.05 - $2.48
Current vs Fair Value SLIGHTLY HIGH

Support & Resistance Levels

Support Level $2.13
Resistance Level $2.49
Current Trend Strong Uptrend
Technical data as of Mar 31, 2026

Fundamental Context

Forward P/E (Next Year Est.) -2.83
Wall Street Target $5.50 (+122.7%)
Revenue Growth (YoY) -19.2%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: March 31, 2026 11:13 PM ET
Data refreshes hourly during market hours. Next update: 12:13 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Parison SELL 474 shares 2026-03-03
Gilmore Neil O'neill SELL 5394 shares 2026-03-03
Linda Burkly SELL 749 shares 2026-03-03

Unlock Insider Activity

See real-time buying/selling by company executives for EDIT.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ONC
BeiGene, Ltd.
STRONG BUY
24 analysts
$411 52 HOLD
INSM
Insmed Inc
STRONG BUY
19 analysts
$213 66 BUY
ACLX
Arcellx Inc
STRONG BUY
18 analysts
$111 57 HOLD
IMVT
Immunovant Inc
STRONG BUY
14 analysts
$40 60 HOLD
RYTM
Rhythm Pharmaceuticals I…
STRONG BUY
12 analysts
$138 57 HOLD

More Analysis for EDIT

EDIT Technical Chart EDIT Price Prediction EDIT Earnings Date EDIT Investment Advisor EDIT Fair Price Analyzer EDIT Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals